Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Gains from Sales and Divestitures (2024 - 2025)

Historic Gains from Sales and Divestitures for Insight Molecular Diagnostics (IMDX) over the last 2 years, with Q3 2025 value amounting to $20000.0.

  • Insight Molecular Diagnostics' Gains from Sales and Divestitures rose 40000.0% to $20000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $20000.0, marking a year-over-year increase of 40000.0%. This contributed to the annual value of $17000.0 for FY2024, which is N/A changed from last year.
  • Per Insight Molecular Diagnostics' latest filing, its Gains from Sales and Divestitures stood at $20000.0 for Q3 2025, which was up 40000.0% from $18000.0 recorded in Q2 2025.
  • In the past 5 years, Insight Molecular Diagnostics' Gains from Sales and Divestitures registered a high of $20000.0 during Q3 2025, and its lowest value of $4000.0 during Q2 2024.